IQVIA leads S&P 500 on strong Q2 earnings, better-than-expected guidance
IQVIA is leading the S&P 500 in early trading after the provider of clinical research services to the pharmaceutical industry posted stronger-than-expected Q2 earnings and offered full-year sales guidance that was higher than the Street expected.
Shortly before 10:30 a.m. ET, the stock was on track for its best day since March 2020, when the market priced in a surge in sales related to outbreak of Covid.
It’s a much-needed rally for a stock that’s been something of a dog over the last year, falling 35% over the last 12 months compared to a 13% gain for the S&P 500.
It’s a much-needed rally for a stock that’s been something of a dog over the last year, falling 35% over the last 12 months compared to a 13% gain for the S&P 500.